SCHEMBL6988647

SCHEMBL6988647

O=C1CCN(S(=O)(=O)c2ccc3oc4ccccc4c3c2)CC1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.78
L3MBTL1 Q9Y468 1/20 0.63
TSHR P16473 3/20 0.62
KDM4E B2RXH2 2/20 0.56
HTT P42858 2/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C19 P33261 1/20 0.56
NPSR1 Q6W5P4 2/20 0.52
USP2 O75604 2/20 0.52
LMNA P02545 2/20 0.52
KMT2A Q03164 4/20 0.49
MMP8 P22894 4/20 0.47
ALDH1A1 P00352 3/20 0.47
MMP3 P08254 2/20 0.47
MEN1 O00255 2/20 0.47
ADRB3 P13945 2/20 0.46
HPGD P15428 2/20 0.46
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27750066 0.78 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1TSHRKDM4EHTT
SCHEMBL2818655 0.75 SMN1; SMN2 (0.63) SMN1; SMN2L3MBTL1TSHRKDM4EHTT
SCHEMBL12719721 0.74 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1TSHRKDM4EHTT
SCHEMBL3201970 0.74 SMN1; SMN2 (0.62) SMN1; SMN2L3MBTL1TSHRKDM4EHTT
SCHEMBL12655865 0.74 MCOLN3 (0.71) SMN1; SMN2TSHRHTTLMNAKMT2A
Hydrochloric Acid SCHEMBL1628271 0.74 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1TSHRKDM4EHTT
SCHEMBL3209872 0.74 HSD11B1 (0.64) SMN1; SMN2L3MBTL1TSHRKDM4EHTT
Water SCHEMBL18832247 0.73 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1TSHRKDM4EHTT
Hydrochloric Acid SCHEMBL9145969 0.73 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1TSHRKDM4EHTT
SCHEMBL7074421 0.73 SMN1; SMN2 (0.60) SMN1; SMN2L3MBTL1TSHRKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6649603-B2 For therapy of metabolic disorders related to insulin resistance or hyperglycemia WYETH 2003-11-18 US disclosed
EP-1328512-A2 CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS Wyeth (US) 2003-07-23 EP disclosed
US-20030027797-A1 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists WYETH (US) 2003-02-06 US disclosed
US-6498170-B2 4-((2S)-3-(1-(4-BUTOXY-BENZENESULFONYL)-AZETIDIN-3-YLAMINO)-2 -HYDROXY- PROPOXY)-PHENOL FOR EXAMPLE; HYPOGLYCEMIC AGENT; INCREASING LEAN MEAT TO FAT RATIO IN MAMMALS WYETH 2002-12-24 US disclosed
US-20020022605-A1 Cyclamine sulfonamides as beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-02-21 US disclosed
WO-2002006221-A2 CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022605-A1 Cyclamine sulfonamides as beta-3 adrenergic receptor agonists ADRB3, ADRB1, ADRB2 SMN1; SMN2 2197/4885L3MBTL1 3906/4885TSHR 59/4885
US-20030027797-A1 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists ADRB3, ADRB1, ADRB2 SMN1; SMN2 2485/4885L3MBTL1 3761/4885TSHR 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.